



truscreen  
a world without  
cervical cancer

## NZX/ASX Announcement

18 March 2024

NZX Limited  
Wellington

### TruScreen Share Placement and Rights Offer Raises NZ\$2.6 million

Truscreen Group Limited (NZX/ASX:TRU) (Truscreen or Company) is pleased to advise that the recent Placement and Rights Offer capital raise concluded at just over NZ\$2.6 million, with NZ\$1,236,000, before costs, raised in a share placement and NZ\$1.4 million through the renounceable Rights Offer.

#### Results of the Rights Offer

TruScreen advise that it closed its 1 for 3 pro rata renounceable rights offer ("Rights Offer"), on 13 March 2024.

The over subscription bookbuild price was set by the board at NZ\$0.02 or A\$0.0187, the same price as the Rights Offer. Approximately 70 million new shares were taken up by Eligible Shareholders from their entitlements and over subscription applications, raising approximately NZ\$1.4 million.

#### Placement

TruScreen has also placed an additional approximately 61.8 million new ordinary fully paid shares at NZ\$0.02 (raising NZD\$1,236,000, before costs) in accordance with the 15% Placement Rule.

#### Allotment of new shares

Settlement, allotment and trading in the new shares under the Rights Offer, and the Placement is expected to occur on or before 20 March 2024 under the existing ticker "TRU".

Non-executive Chairman, Tony Ho commented, "*this is an outstanding result and demonstrates the confidence that investors have in the Company following solid progress this financial year with the inclusion of TruScreen Ultra2 device on Chinese Obstetrics and Gynaecological Association (COGA) Blue Book (national guideline) and additional listing in the national guideline of China Society of Colposcopy and Cervical Pathology (CSCCP). TruScreen Ultra2 was also listed on Vietnam's Ministry of Health, National Technical List. In recent months, Mexico's regulator, COFEPRIS approved TruScreen Ultra2 device for use in Mexico's Public Health Sector.*

*I would like to thank existing shareholders for their ongoing support, and welcome new shareholders to the register as we look forward to FY2025."*

-ENDS-

This announcement has been approved by the Board.

Guy Robertson  
Company Secretary

For more information, visit [www.truscreen.com](http://www.truscreen.com) or contact:

Martin Dillon  
Chief Executive Officer  
[martindillon@truscreen.com](mailto:martindillon@truscreen.com)

Guy Robertson  
Chief Financial Officer  
[guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

### About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra<sup>®</sup>, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In financial year 2023 alone, over 140,000\* examinations have been performed with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer"<sup>©</sup>.

To learn more, please visit: [www.truscreen.com/](http://www.truscreen.com/).

*\*Based on Single Use Sensor sales.*